X-396 (ensartinib) clinical trials

eXalt3: Study Comparing X-396 (Ensartinib) to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients

This study compares two medicines, X-396 (ensartinib) and crizotinib, for people with a specific type of lung cancer called ALK-positive non-small cell lung cancer. It looks at how well each medicine works and if they are safe.